Porton Pharma Solutions reduces capital by cancelling repurchased shares

Porton Pharma Solutions has completed the cancellation of 2,022,344 repurchased shares, representing 0.37% of its total share capital prior to the cancellation. This action, finalized on November 4, 2025, with China Securities Depository and Clearing Corporation Limited Shenzhen Branch, has reduced the company's total share capital from 545,464,520 shares to 543,442,176 shares. The repurchased shares were initially acquired between August 29, 2022, and November 21, 2022.

The shares were repurchased at a maximum price of 59.15 yuan per share and a minimum price of 42.09 yuan per share, totaling 99,999,172.81 yuan (excluding transaction fees). The company had originally approved a share repurchase plan on August 4, 2022, intending to use the shares for equity incentives or employee stock ownership plans. However, due to the expiry of the retention period for the 2022 repurchased shares on November 21, 2025, the untransferred shares were cancelled.

The cancellation impacts the company's share structure, reducing the number of unlimited tradable shares. The proportion of restricted tradable shares remains at 8.20%, while unlimited tradable shares now account for 91.80% of the total share capital. The company's board of directors has been authorized to handle the subsequent registration of changes in registered capital and amendments to the Articles of Association.